Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Clin Nurs Res ; 32(3): 648-659, 2023 03.
Article in English | MEDLINE | ID: covidwho-2260525

ABSTRACT

Treatment adherence is a fundamental aspect of heart failure (HF) management. This study aimed to explore the experiences of facilitators and inhibitors of treatment adherence in patients with HF. This descriptive qualitative study was conducted from May 2020 to June 2021. Participants including people with HF, their family caregivers and physicians, and nurses were selected purposefully, with the aim of obtaining sufficient information power. Semi-structured interviews were used to collect data. Data were analyzed using thematic analysis. Two main themes "the driving forces behind treatment adherence" and "the deterrent forces behind treatment adherence" emerged from the analysis. The first theme contained the following subthemes: "supportive family," "positive personality characteristics," and "having health literacy." The second theme consisted of "negligence," "psychological problems," "cultural, social, and economic problems," "physical limitations," and "lack of self-care management knowledge." Nurses can consider facilitators and inhibitors of treatment adherence in designing educational and care programs for patients with HF.


Subject(s)
Heart Failure , Treatment Adherence and Compliance , Humans , Qualitative Research , Heart Failure/drug therapy , Heart Failure/psychology , Self Care/psychology , Caregivers
2.
Eur J Cardiovasc Nurs ; 21(5): 438-445, 2022 06 30.
Article in English | MEDLINE | ID: covidwho-1506927

ABSTRACT

BACKGROUND: During the COVID-19 outbreak, patients with left ventricular assist device (LVAD) faced several changes in their daily life. However, the effects of these changes on the patients' lived experiences are not still investigated. AIMS: The current study explored the lived experience of people with left ventricular assist device (LVAD) during the COVID-19 pandemic. During the COVID-19 outbreak, people with LVADs faced several changes in their daily life. However, the effects of these changes on the patients' lived experiences are not still investigated. METHODS AND RESULTS: Qualitative data analysis was conducted employing the interpretative phenomenological analysis approach. We followed the Standards for Reporting Qualitative Research guidelines. Eight male participants with LVAD aged from 65 to 82 were interviewed. Overall, two main themes ('Worsening of psychological distress' and 'Moving forward') and eight sub-themes emerged from the qualitative analysis. CONCLUSIONS: People with LVADs experienced feelings of worry and solitude related to the risk of being infected or not receiving adequate treatment due to changes in the healthcare system during the pandemic; however, they managed to move forward with their lives using different strategies for dealing with the difficult situation.


Subject(s)
COVID-19 , Heart Failure , Heart-Assist Devices , Emotions , Heart Failure/psychology , Heart Failure/therapy , Heart-Assist Devices/psychology , Humans , Male , Pandemics , Qualitative Research
3.
ESC Heart Fail ; 8(2): 1324-1332, 2021 04.
Article in English | MEDLINE | ID: covidwho-1037482

ABSTRACT

AIMS: The coronavirus disease 2019 (COVID-19) pandemic has created significant challenges to healthcare globally, necessitating rapid restructuring of service provision. This questionnaire survey was conducted amongst adult heart failure (HF) patients in the United Kingdom (UK), to understand the impact of COVID-19 upon HF services. METHODS AND RESULTS: The survey was conducted by the Pumping Marvellous Foundation, a UK HF patient charity. 'Survey Monkey' was used to disseminate the questionnaire in the Pumping Marvellous Foundation 's online patient group and in 10 UK hospitals (outpatient hospital and community HF clinics). There were 1050 responses collected (693/1050-66% women); 55% (579/1050) were aged over 60 years. Anxiety level was significantly higher regarding COVID-19 (mean 7 ± 2.5 on anxiety scale of 0 to 10) compared with anxiety regarding HF (6.1 ± 2.4; P < 0.001). Anxiety was higher amongst patients aged ≤60 years about HF (6.3 ± 2.2 vs. 5.9 ± 2.5 in those aged >60 years; P = 0.005) and COVID-19 (7.3 ± 2.3 vs. 6.7 ± 2.6 those aged >60 years; P < 0.001). Sixty-five per cent of respondents (686/1050) reported disruption to HF appointments (cancellation or postponement) during the lockdown period. Thirty-seven per cent reported disruption to medication prescription services, and Thirty-four per cent reported inability to access their HF teams promptly. Thirty-two per cent expressed reluctance to attend hospital (25% stated they would only attend hospital if there was no alternative, and 7% stated that they would not attend hospital at all). CONCLUSIONS: The COVID-19 pandemic has caused significant anxiety amongst HF patients regarding COVID-19 and HF. Cancellation or postponement of scheduled clinic appointments, investigations, procedures, prescription, and monitoring services were implicated as sources of anxiety.


Subject(s)
COVID-19/epidemiology , Communicable Disease Control , Heart Failure/psychology , Heart Failure/therapy , Telemedicine/organization & administration , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Anxiety/epidemiology , COVID-19/prevention & control , Female , Humans , Male , Middle Aged , Patient Preference , Surveys and Questionnaires , United Kingdom , Young Adult
4.
Curr Probl Cardiol ; 46(4): 100737, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-898666

ABSTRACT

BACKGROUND: The COVID-19 pandemic's mental health consequences remain unknown. AIM: To assess the mental health status of ambulatory cardiometabolic patients during COVID-19 pandemic lockdown in Spanish speaking Latin American countries. METHODS: Cardiometabolic patients without COVID-19 evidence in 13 Latin American countries answered a survey between June 15th and July 15th, 2020. The Diagnosis Manual of Mental Disorders fifth edition was used to identify the presence of major depressive symptoms. RESULTS: The sample included 4216 patients, 1590 (37.71%; IC95% 36.24-39.19) were considered suffering major depression. Female gender, consuming ≥5 medications day, physical activity <100 minutes weekly, low fruits and vegetables intake, poor treatment adherence, reduced food consumption were independently associated to the presence of major depressive symptoms. CONCLUSIONS: The CorCOVID Latam Psy study showed that one-third of the Latin American Spanish speaking population is suffering from major depressive symptoms during the COVID-19 outbreak.


Subject(s)
COVID-19 , Cardiovascular Diseases/epidemiology , Depression/epidemiology , Depressive Disorder, Major/epidemiology , Diabetes Mellitus/epidemiology , Metabolic Syndrome/epidemiology , Adult , Aged , Cardiovascular Diseases/psychology , Coronary Artery Disease/epidemiology , Coronary Artery Disease/psychology , Depression/psychology , Depressive Disorder, Major/psychology , Diabetes Mellitus/psychology , Diet/statistics & numerical data , Dyslipidemias/epidemiology , Dyslipidemias/psychology , Eating , Exercise/psychology , Female , Fruit , Heart Failure/epidemiology , Heart Failure/psychology , Humans , Hypertension/epidemiology , Hypertension/psychology , Latin America/epidemiology , Male , Mental Health , Metabolic Syndrome/psychology , Middle Aged , SARS-CoV-2 , Sex Factors , Stroke/epidemiology , Stroke/psychology , Surveys and Questionnaires , Treatment Adherence and Compliance/psychology , Treatment Adherence and Compliance/statistics & numerical data , Vegetables
6.
G Ital Cardiol (Rome) ; 21(10): 750-756, 2020 Oct.
Article in Italian | MEDLINE | ID: covidwho-791898

ABSTRACT

BACKGROUND: During the COVID-19 pandemic, non-urgent outpatient activities were temporarily suspended. The aim of this study was to assess the impact of this measure on the management of the heart failure outpatient clinic at our institution. METHODS: We analyzed the clinical outcome of 110 chronic heart failure patients (mean age 73 ± 9 years) whose follow-up visit had been delayed. RESULTS: At their last visit before the lockdown, 80.9% was in NYHA class II, had an ejection fraction of 37 ± 7%, and B-type natriuretic peptide level was moderately elevated (266 ± 138 pg/ml). All patients received loop diuretics, 97.2% beta-blockers, 64.9% an aldosterone antagonist, 60.9% sacubitril/valsartan (S/V), and 72.2% of the remaining patients were on angiotensin-converting enzyme inhibitor or valsartan therapy. Patients were contacted by phone during and at the end of the lockdown period to fix a new appointment and underwent a structured interview to assess their clinical conditions and ongoing therapy and to verify whether they had contracted SARS-CoV-2 infection. Twelve patients (13.2%) contracted COVID-19. None was hospitalized for worsening heart failure or reported defibrillator shocks and none changed autonomously the prescribed therapy. Overall, 75% of patients reported stable or improved general well-being from the last in-person visit, while 25% described subjective worsening due to the social effect of the pandemic. Unchanged body weight and blood pressure values were reported by 86% and 78.4% of patients, respectively. Lower blood pressure values compared to baseline were recorded in 15.2% of patients on conventional renin-angiotensin system inhibition vs 21% of those on S/V, one of whom had to down-titrate S/V for persistent but asymptomatic hypotension; 4 patients up-titrated S/V to 200 mg/day following phone indications. CONCLUSIONS: Cancellation of scheduled follow-up visits during 3 months did not have significant negative effects in a cohort of stable patients with chronic heart failure on optimized medical therapy. Telephone support was effective in keeping connections with the patients during the lockdown, allowing appropriate management and implementation of drug therapy. In particular, patients who received S/V were not affected by delays in scheduled visits, confirming the tolerability and safety of this novel therapy in terms of both clinical and biohumoral parameters.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Heart Failure/drug therapy , Pneumonia, Viral/epidemiology , Quarantine , Adrenergic beta-Antagonists/therapeutic use , Aged , Ambulatory Care Facilities , Aminobutyrates/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Biphenyl Compounds , COVID-19 , Chronic Disease , Continuity of Patient Care/organization & administration , Coronavirus Infections/diagnosis , Coronavirus Infections/psychology , Delivery of Health Care , Disease Progression , Drug Combinations , Female , Heart Failure/blood , Heart Failure/psychology , Humans , Italy/epidemiology , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , Natriuretic Peptide, Brain/blood , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/psychology , Recurrence , SARS-CoV-2 , Sodium Potassium Chloride Symporter Inhibitors/therapeutic use , Stroke Volume , Telephone , Tetrazoles/therapeutic use , Valsartan , Withholding Treatment
SELECTION OF CITATIONS
SEARCH DETAIL